<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784689</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS 21-0012</org_study_id>
    <nct_id>NCT04784689</nct_id>
  </id_info>
  <brief_title>Host Immune Response to Novel RNA COVID-19 Vaccination</brief_title>
  <official_title>Host Immune Response to Novel RNA COVID-19 Vaccination in Patients With Cancer (CTMS# 21-0012)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the antibody response level in patients with cancer to the COVID-19 vaccination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody response level in patients with cancer to the COVID-19 vaccination.</measure>
    <time_frame>Pre dose on day 1 (baseline), pre dose on day 21, day 35, 6 months, 12 month and 18 months</time_frame>
    <description>Antibody response change over time</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19 Vaccine</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Prospective - Cancer Patients that have received COVID-19 Vaccination</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine</intervention_name>
    <description>COVID-19 Vaccine</description>
    <arm_group_label>Prospective - Cancer Patients that have received COVID-19 Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mays Cancer Center patients eligible to receive the COVID-19 vaccination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Must be eligible to receive the COVID19 vaccination by standard and current CDC&#xD;
             guidelines. This includes all RNA vaccinations grant EUA status by the FDA&#xD;
&#xD;
          3. Diagnosed with any malignancy within the last 5 years, with the exception of&#xD;
             early-stage squamous cell skin cancer, early-stage basal cell skin carcinoma and&#xD;
             noninvasive pathology such as DCIS (Ductal Carcinoma in-situ)&#xD;
&#xD;
          4. Able to provide informed consent&#xD;
&#xD;
          5. Patients can be on any form of treatment (including clinical trials) and at any stage&#xD;
             (including remission) in their cancer therapy plan - including chemotherapy,&#xD;
             immunotherapy, targeted therapy, hormonal therapy, radiation, palliative care or&#xD;
             observation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously documented COVID infection&#xD;
&#xD;
          2. Previously enrolled in a vaccination trial and either still blinded or known to&#xD;
             receive the vaccination. (Those patients on a trial but known to receive a placebo&#xD;
             dose are eligible to enroll)&#xD;
&#xD;
          3. Contraindication to the vaccination based on current CDC guideline such as know&#xD;
             allergic reactions that increase risk of having an allergic reaction to a COVID RNA&#xD;
             vaccination. This includes but is not limited to:&#xD;
&#xD;
               -  Severe allergic reaction (e.g., anaphylaxis) after a previous dose of an mRNA&#xD;
                  COVID-19 vaccine or any of its components&#xD;
&#xD;
               -  Immediate allergic reaction of any severity to a previous dose of an mRNA&#xD;
                  COVID-19 vaccine or any of its components (including polyethylene glycol [PEG])&#xD;
&#xD;
               -  Immediate allergic reaction of any severity to polysorbate (due to potential&#xD;
                  cross-reactive hypersensitivity with the vaccine ingredient PEG)&#xD;
&#xD;
          4. Pregnant or breastfeeding&#xD;
&#xD;
          5. Unable to comply with study related procedures as determined by the study team.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dimpy Shah, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimpy Shah, MD PhD</last_name>
    <phone>210-562-6503</phone>
    <email>shahdp@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mays Cancer Center, UT Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <email>CTRCReferral@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Dimpy Shah, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kate Lathrop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Kate Lathrop</investigator_full_name>
    <investigator_title>Clinical Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

